Biosimilars – Market Events And Forecast – Immunology
In 2020, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this therapy area totaled approximately $3.2 billion. Throughout the 2020-2030 forecast period, increasing numbers of branded biologics in the immunology space are set to lose patent protection, and biosimilars will launch and reduce branded biologics’ patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Biosimilars - Market Events And Forecast - Immunology
Market Forecast in the Major Pharmaceutical Markets
Major-Market Forecast: Immune Biologics
Terminology
Overarching Forecast Assumptions
Overview of Immune Biological Brands in Forecast
Overview of Approved Immune Biologics
Biosimilar Entry Assumptions for Immune Biologics
Overview of Biosimilars in Immune Disease Assumptions
Drug-Specific Forecast Assumptions
Remicade
Outlook for Remicade
First Biosimilars of Remicade in the Major Pharmaceutical Markets
Order of Entry in the United States
Order of Entry in the EU5
Order of Entry in Japan
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Remicade: United States
Patient Share by Specialty for Remicade: EU5
Patient Share by Specialty for Remicade: Japan
Remicade Sales Forecast for the United States: 2020-2030
Remicade Sales Forecast for the EU5: 2020-2030
Remicade Sales Forecast for Japan: 2020-2030
Enbrel
Outlook for Enbrel
First Biosimilars of Enbrel in the Major Pharmaceutical Markets
Order of Entry in the United States
Order of Entry in the EU5
Order of Entry in Japan
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Enbrel: United States
Patient Share by Specialty for Enbrel: EU5
Patient Share by Specialty for Enbrel: Japan
Enbrel Sales Forecast for the United States: 2020-2030
Enbrel Sales Forecast for the EU5: 2020-2030
Enbrel Sales Forecast for Japan: 2020-2030
Rituxan / MabThera
Outlook for Rituxan / MabThera
First Biosimilars of Rituxan / MabThera in the Major Pharmaceutical Markets
Order of Entry in the United States
Order of Entry in the EU5
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Rituxan Sales Forecast for the United States (Immunology): 2020-2030
MabThera Sales Forecast for the EU5 (Immunology): 2020-2030
Rituxan Sales Forecast for the United States (Immunology and Oncology): 2020-2030
MabThera Sales Forecast for the EU5 (Immunology and Oncology): 2020-2030
Humira
Outlook for Humira
First Biosimilars of Humira in the Major Pharmaceutical Markets
Order of Entry in the United States
Order of Entry in the EU5
Order of Entry in Japan
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Humira: United States
Patient Share by Specialty for Humira: EU5
Patient Share by Specialty for Humira: Japan
Humira Sales Forecast for the United States: 2020-2030
Humira Sales Forecast for the EU5: 2020-2030
Humira Sales Forecast for Japan: 2020-2030
Actemra / RoActemra
Outlook for Actemra / RoActemra
First Biosimilars of Actemra / RoActemra in the Major Pharmaceutical Markets
Order of Entry in the United States
Order of Entry in the EU5
Order of Entry in Japan
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Actemra Sales Forecast for the United States: 2020-2020
RoActemra Sales Forecast for the EU5: 2020-2030
Actemra Sales Forecast for Japan: 2020-2030
Stelara
Outlook for Stelara
First Biosimilars of Stelara in the Major Pharmaceutical Markets
Order of Entry in the United States
Order of Entry in the EU5
Order of Entry in Japan
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Stelara: United States
Patient Share by Specialty for Stelara: EU5
Patient Share by Specialty for Stelara: Japan
Stelara Sales Forecast for the United States: 2020-2030
Stelara Sales Forecast for the EU5: 2020-2030
Stelara Sales Forecast for Japan: 2020-2030
Cimzia
Outlook for Cimzia
First Biosimilars of Cimzia in the Major Pharmaceutical Markets
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Cimzia: United States
Patient Share by Specialty for Cimzia: EU5
Patient Share by Specialty for Cimzia: Japan
Cimzia Sales Forecast for the United States: 2020-2030
Cimzia Sales Forecast for the EU5: 2020-2030
Cimzia Sales Forecast for Japan: 2020-2030
Simponi
Outlook for Simponi
First Biosimilars of Simponi in the Major Pharmaceutical Markets
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Simponi: United States
Patient Share by Specialty for Simponi: EU5
Patient Share by Specialty for Simponi: Japan
Simponi Sales Forecast for the United States: 2020-2030
Simponi Sales Forecast for the EU5: 2020-2030
Simponi Sales Forecast for Japan: 2020-2030
Orencia
Outlook for Orencia
First Biosimilars of Orencia in the Major Pharmaceutical Markets
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Orencia Sales Forecast for the United States: 2020-2030
Orencia Sales Forecast for the EU5: 2020-2030
Orencia Sales Forecast for Japan: 2020-2030
Cosentyx
Outlook for Cosentyx
First Biosimilars of Cosentyx in the Major Pharmaceutical Markets
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Cosentyx: United States
Patient Share by Specialty for Cosentyx: EU5
Patient Share by Specialty for Cosentyx: Japan
Cosentyx Sales Forecast for the United States: 2020-2030
Cosentyx Sales Forecast for the EU5: 2020-2030
Cosentyx Sales Forecast for Japan: 2020-2030
Taltz
Outlook for Taltz
First Biosimilars of Taltz in the Major Pharmaceutical Markets
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Patient Share by Specialty for Taltz: United States
Patient Share by Specialty for Taltz: Japan
Taltz Sales Forecast for the United States: 2020-2030
Taltz Sales Forecast for Japan: 2020-2030
Entyvio
Outlook for Entyvio
First Biosimilars of Entyvio in the Major Pharmaceutical Markets
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturer Price Assumptions
Entyvio Sales Forecast for the United States: 2020-2030
Entyvio Sales Forecast for the EU5: 2020-2030
Entyvio Sales Forecast for Japan: 2020-2030
Yashu Malhotra
Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
Hamzah Aideed, M.Sc.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.